Source: Annual Congress 2001 - Updates of asthma therapy in children
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. A. Janahi, C. C. Macias, R. H. Moore (Doha, Qatar; Houston, United States Of America). Full versus partial β2-agonist in severe, acute asthma in children. Eur Respir J 2001; 16: Suppl. 31, 835

Member's Comments

No comment yet.

Related content which might interest you: Predictors of severe exacerbations in patients with moderate and severe asthma Source: International Congress 2018 – Determinants and monitoring of asthma control Year: 2018 Treating acute severe asthma attacks in children: using aminophylline Source: Breathe, 16 (4) 200081; 10.1183/20734735.0081-2020 Year: 2020 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections Year: 2021 Distribution of biomarkers in severe asthma and severe uncontrolled asthma Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research Year: 2021 Evolution from mild to severe asthma; the severe asthma clinic perspective Source: International Congress 2019 – Clinical implications of asthma management Year: 2019 New rhinovirus strains predominate in children with acute asthma and are associated with more severe exacerbations Source: Annual Congress 2009 - How viruses, allergic rhinitis and air pollution affect childhood asthma Year: 2009 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Impact of moderate and severe exacerbations in severe COPD patients Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018 Management of difficult-to-treat severe asthma Source: Eur Respir Mon 2011; 51: 282-296 Year: 2011 Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Severe asthma in children Source: International Congress 2015 – Fingerprinting severe asthma Year: 2015 Severe asthma in children Source: CME Online 2011 Year: 2011 Relationship between benralizumab exposure and asthma exacerbation rate for patients with severe asthma Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017 Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma Source: ERJ Open Res, 6 (1) 00204-2019; 10.1183/23120541.00204-2019 Year: 2020 Factors resulting in uncontrolled severe persistent asthma in children Source: Eur Respir J 2004; 24: Suppl. 48, 20s Year: 2004 Management of severe asthma in children Source: Virtual Congress 2020 – Reducing the burden of asthma Year: 2020 Management of severe asthma in children Source: Annual Congress 2010 - ERS/[italic]Lancet[/italic] Asthma Year: 2010 Management of severe asthma in children Source: International Congress 2018 – ME11 Management of severe asthma in children FULLY BOOKED Year: 2018 ME11 Management of severe asthma in children Source: Paris 2018 - Educational material Year: 2018